Markets
AZN

Better Coronavirus Stock: AstraZeneca or Moderna?

Only three coronavirus vaccine candidates with the potential to be marketed in the U.S. are currently in late-stage testing. AstraZeneca (NYSE: AZN) and Moderna (NASDAQ: MRNA) claim two of the three.

If you think that these two stocks are beating the market so far in 2020, you're right. Moderna has been a much bigger winner than AstraZeneca year to date. But which of these coronavirus stocks is the better long-term pick? 

Close-up of gloved hand holding vaccine bottle labeled COVID-19 vaccine

Image source: Getty Images.

The case for AstraZeneca

Probably the best argument for buying AstraZeneca instead of Moderna is that it's less risky. If Moderna's COVID-19 vaccine candidate runs into problems in late-stage testing, its shares will almost certainly plunge. AstraZeneca, on the other hand, can more readily absorb any setbacks because of its diversified portfolio.

We've already seen this happen. AstraZeneca announced on Sept. 9 that it was temporarily pausing its phase 3 testing of coronavirus vaccine candidate AZD1222 after a participant experienced an unexplained illness. Its shares slipped only 3% and quickly bounced back.

Investors shouldn't worry too much about AZD1222. AstraZeneca already received the green light to resume late-stage clinical trials in the U.K. Scientists with the University of Oxford, which initially developed AZD1222, think that the patient illness that resulted in the clinical trial pause probably wasn't related to the vaccine. 

AstraZeneca should still have a pretty good chance at achieving commercial success with AZD1222. More importantly, the company has many other potential growth drivers. Three of AstraZeneca's cancer drugs (Tagrisso, Imfinzi, and Lynparza) delivered year-over-year sales growth of at least 45% in the first half of 2020. Four of the company's other drugs generated double-digit percentage growth.

In addition, AstraZeneca's new drugs are picking up solid momentum, especially blood cancer drug Calquence. The company's pipeline includes 166 programs, nine of which are new candidates in late-stage testing.

AstraZeneca's shares trade at 22 times expected earnings. That valuation isn't all that high, though, considering that analysts expect the company to grow its earnings by an average of 19% annually over the next five years.

The case for Moderna

Moderna is admittedly riskier than AstraZeneca. But that higher level of risk also means that the biotech stock should deliver much higher gains if COVID-19 vaccine candidate mRNA-1273 is successful in late-stage testing.

The chances of mRNA-1273 achieving this success appear to be pretty good at this point. Phase 1 results for the messenger RNA vaccine were promising: mRNA-1273 produced strong immune responses in participants with no severe adverse reactions.

Moderna slowed down enrollment in its phase 3 study of mRNA-1273 to increase the diversity of participants. That slowdown has paid off, though. As of Sept. 16, around 28% of participants in the study were from diverse communities. It's possible that Moderna could secure FDA emergency use authorization for mRNA-1273 before the end of this year. 

Tremendous growth prospects are already baked into Moderna's share price. However, the market opportunity for mRNA-1273 alone gives the stock room to run. And if mRNA-1273 wins regulatory approvals, investors will likely see a lot more value in the rest of Moderna's pipeline.

That pipeline includes six other prophylactic mRNA vaccine candidates in clinical testing. Moderna also has five mRNA clinical-stage programs targeting cancer plus an antibody against chikungunya virus in phase 1 testing. The company has even partnered with AstraZeneca to develop one of its experimental mRNA cancer therapies along with a therapy targeting coronary artery disease.

Better coronavirus stock?

My view is that the better coronavirus stock to buy between AstraZeneca and Moderna depends on your investing style. If you're a more conservative investor, AstraZeneca is definitely the better pick. It's less risky than Moderna and offers solid growth prospects plus an attractive dividend.

On the other hand, aggressive investors will probably prefer Moderna. The biotech could become much larger over the next decade and beyond if its mRNA programs deliver on their potential.

10 stocks we like better than AstraZeneca
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AstraZeneca wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 1, 2020

 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN MRNA

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More